Abstract
Background and Aims: Evolocumab, an anti-PCSK9 antibody, is used to reduce LDL-cholesterol level in patients with cardiovascular diseases. At the same time, it was found, that PCSK9 itself is involved not only in lipids metabolism but also in inflammatory process. The aim of our study was to investigate the effects of the evolocumab treatment on T-cell activation in human atherosclerotic plaques.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
